Qternmet XR contains dapagliflozin, saxagliptin and metformin hydrochloride in an extended-release tablet formulation. It was used in the treatment of adults with type-2 diabetes, but has now been discontinued.
Qternmet XR was available as extended-release tablets in the following strengths:
- dapagliflozin 2.5 mg / saxagliptin 2.5 mg / metformin hydrochlporide 1000 mg
- dapagliflozin 5 mg / saxagliptin 2.5 mg / metformin hydrochlporide 1000 mg
- dapagliflozin 5 mg / saxagliptin 5 mg / metformin hydrochlporide 1000 mg
- dapagliflozin 10 mg / saxagliptin 5 mg / metformin hydrochlporide 1000 mg
Qternmet XR was the first combination containing all three drugs. Dapagliflozin, saxagliptin and metformin hydrochloride are also contained in single ingredient products and combinations containing two of the drugs.
Dapagliflozin is a sodium‑glucose cotransporter-2 (SGLT-2) inhibitor. Dapagliflozin is also contained in the following single ingredient and combination drug products:
- dapagliflozin (Farxiga)
- dapagliflozin and saxagliptin (Qtern)
- dapagliflozin and metformin hydrochloride (Xigduo XR)
Saxagliptin is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor. Saxagliptin is also contained in the following single ingredient and combination drug products:
- saxagliptin (Onglyza)
- dapagliflozin and saxagliptin (Qtern)
- saxagliptin and metformin hydrochloride (Kombiglyze XR)
Metformin hydrochloride is a biguanide. Metformin hydrochloride is also contained in the following single ingredient and combination drug products:
- metformin hydrochloride (Fortamet, Glucophage, Glucophage XR, Glumetza, Riomet)
- dapagliflozin and metformin hydrochloride (Xigduo XR)
- saxagliptin and metformin hydrochloride (Kombiglyze XR)